Osborne D P, Katz D H
J Immunol. 1977 Apr;118(4):1449-55.
The growth of an ascitic murine plasmacytoma, MOPC 315, can be retarded in CAF1 hybrid host mice by the i.p. injection of donor lymphoid cells. The graft-vs-host reaction can be established by a variety of donor cells, including parental BALB/c and A/J and congenic inbred B10.D2 which share the major histocompatibility locus with BALB/c(H-2d). Optimal results are consistently obtained when parental BALB/c spleen cells are injected before tumor inoculation, and a second dose of donor spleen cells injected 1 week later. This aloogeneic effect on tumor growth is manifested by delayed appearance of the tumor and prolonged host survival. Pathologic studies on the ascites tumor indicated that the allogeneic effect suppresses the initial appearance and early growth of the plasmacytoma. However, once established, MOPC 315 grows rapidly and fatally in both control mice and recipients of donor lymphoid cells. Further, a subcutaneous implant of MOPC 315 is suppressed by an allogeneic effect established either i.v. with BALB/c spleen cells before tumor inoculation or by BALB/c spleen cells administered subcutaneously at the time of MOPC 315 implant. Thirty percent of mice treated by i.v. or subcutaneous donor lymphoid cells were tumor free at 150 days after tumor inoculation.
腹腔注射供体淋巴细胞可使杂种宿主小鼠CAF1中腹水型小鼠浆细胞瘤MOPC 315的生长受到抑制。多种供体细胞均可引发移植物抗宿主反应,包括与BALB/c(H-2d)共享主要组织相容性位点的亲代BALB/c和A/J以及同基因近交系B10.D2。在肿瘤接种前注射亲代BALB/c脾细胞,并在1周后注射第二剂供体脾细胞,始终能获得最佳结果。这种对肿瘤生长的同种异体效应表现为肿瘤出现延迟和宿主存活期延长。对腹水肿瘤的病理学研究表明,同种异体效应可抑制浆细胞瘤的初始出现和早期生长。然而,一旦形成,MOPC 315在对照小鼠和供体淋巴细胞受体中均迅速生长并导致死亡。此外,MOPC 315的皮下植入物会受到同种异体效应的抑制,这种效应可通过在肿瘤接种前静脉注射BALB/c脾细胞或在植入MOPC 315时皮下注射BALB/c脾细胞来建立。在肿瘤接种后150天,30%接受静脉或皮下供体淋巴细胞治疗的小鼠没有肿瘤。